Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 May 2025 | Story André Damons | Photo André Damons
Research room
Prof Corinna Walsh from the UFS Department of Nutrition and Dietetics explains how the PEA POD® infant body composition analyser works. Dr Balekile Mzangwa, CEO of Universitas Academic Hospital, and Dr Grace London, Chief Director: District Health services at the Free State Department of Health, listens in.

In a significant stride toward improving maternal and child health in the Free State, the Universitas Academic Hospital, in collaboration with the Faculty of Health Sciences at the University of the Free State (UFS), has launched an innovative Research Room which houses the PEA POD® infant body composition analyser and the Dual-Energy X-ray Absorptiometry (DXA) machine used to assess body composition and bone mineral density.

The initiative, which marks a new era in neonatal care and research, aims to integrate cutting-edge technology into routine clinical care. The PEA POD®, a non-invasive device that uses air displacement plethysmography, allows for precise measurement of fat and fat-free mass in newborns – offering a more accurate assessment of growth and nutritional status than traditional methods. 

The research room is a newly renovated and dedicated space adjacent to the maternity and neonatal units, ensuring quick, safe access to the newborns in the hospital. Two full-time MSc Dietetics students have been trained to perform the PEAPOD® assessments and colleagues from Radiography will perform the DXA assessments. This work lays the foundation for an ongoing maternal and infant body composition database –  a valuable resource for research, clinical care, and policy guidance.

Aligned with national health priorities

According to Prof Corinna Walsh from the UFS Department of Nutrition and Dietetics, this initiative is the result of a multidisciplinary collaboration across Paediatrics and Child Health, Obstetrics and Gynaecology, Radiography, Nutrition and Dietetics, to mention just a few of the collaborators. They are optimistic about the dual impact of this project as it advances academic and clinical research in early-life nutrition and growth as well as enhancing patient care at Universitas Hospital – bringing measurable benefits to mothers and their babies, she said. 

“This initiative is well aligned with national health priorities. According to the South African Early Childhood Review 2024, malnutrition in all its forms remains a significant challenge with short- and long-term consequences for mothers and their babies, especially during the first 1 000 days of life, from conception to the second birthday.

“We know from global and local evidence that growth patterns established during early life have profound and lasting effects on an individual’s health, development, and well-being. Our work at the University of the Free State has focused on the nutritional status of pregnant women and the early environments to which infants are exposed, both during and after pregnancy,” said Prof Walsh. 

However, she continued, in previous studies, they faced a significant challenge: the lack of specialised equipment to accurately measure infant body composition. Traditional measures such as weight and length provide only part of the picture.

 

New possibilities in healthcare, science, and service

Dr Mzangwa said the day not only marks the unveiling of state-of-the-art technology, but the beginning of a new chapter in how they will care for and understand the youngest and most vulnerable patients. The PEA POD® and DXA, which is now housed just steps away from the maternity and neonatal wards, symbolise a shared vision between the hospital and the Faculty of Health Sciences at the UFS: a vision grounded in evidence-based care, cutting-edge research, and above all, compassion.

“We express our sincere appreciation to everyone who supported this initiative. We also acknowledge the dedication of all the collaborating departments – Paediatrics and Child Health, Obstetrics and Gynaecology, Radiography, Nutrition and Dietetics –  and thank Prof Corinna Walsh and Dr Lizzy Tabane for their leadership and insight.”

Prof Janse van Vuuren, said: “Today, we do more than open a physical space. We open the door to new possibilities in healthcare, science, and service to the people of our province. It is a shining example of what can be achieved when government and academia come together, united by a common purpose – to improve lives through knowledge, innovation, and care.”

The technologies that will be used in this facility are more than just advanced instruments, they are tools that allow medical staff to better understand the human body in its earliest and most vulnerable stages, as well as throughout the lifespan. With this understanding comes the ability to make informed decisions, to intervene earlier, and to tailor care in ways that truly meet the needs of our patients, said Prof Janse van Vuuren.

“This space is more than a research centre. It is a testament to our commitment to evidence-based care. It is a place where data meets compassion, where science serves humanity. The work that will happen here will not be confined to the walls of academia –  it has the potential to ripple outward into clinics, into hospitals, and into homes. It will shape guidelines, inform policy, and ultimately, improve outcomes for patients across our province and beyond.”


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept